Gregory Panzo, MD
Ophthalmology · Mount Dora, FLNPI 1457354573
Payments from drug & device makers
Across 237 payments — averaging $154.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon Research LLC$28K
- Alcon$4K
- AbbVie$3K
- Novartis$422
- Ivantis, Inc$239
- Bausch & Lomb, A Division Of Bausch Health US, LLC$232
- plus $1K from 17 others
What the payments were for
- Travel & lodging$1,44920%
- Food & beverage$5,59578%
- Gifts$1472%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon Research LLC | 38 | $27,749 |
| Alcon | 62 | $4,196 |
| AbbVie(2 entities) | 63 | $2,610 |
| Novartis | 23 | $422 |
| Ivantis, Inc | 1 | $239 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $232 |
| Sight Sciences, Inc. | 4 | $180 |
| NEW World Medical,inc. | 9 | $176 |
| Carl Zeiss Meditec, Inc. | 2 | $167 |
| Ocular Therapeutix, Inc. | 8 | $147 |
| Rayner Intraocular Lenses Limited | 3 | $124 |
| Oyster Point Pharma, Inc. | 3 | $64 |
| Glaukos Corporation | 2 | $50 |
| Bausch & Lomb Americas Inc. | 2 | $37 |
| Aerie Pharmaceuticals, Inc. | 2 | $36 |
| Shire North American Group Inc | 2 | $31 |
| Dompe US, Inc. | 1 | $26 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $26 |
| Sun Pharmaceutical Industries Inc. | 1 | $25 |
| Eyepoint US, Inc. | 1 | $18 |
| Iridex Corporation | 1 | $15 |
| Amgen | 1 | $14 |
| Mallinckrodt Hospital Products Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$432
- ARGOS$407
- AcrySof$372
- Clareon PanOptix Pro$256
- ORA$247
- Hydrus$239
- OMNI(R) SURGICAL SYSTEM (US)$141
- Unity$125
- Kahook Dual Blade$105
- Clearpath$105
- Ahmed Glaucoma Valve$105
- Streamline$105
- CLARUS 500 Fundus Camera$102
- VYZULTA$100
How this compares
$36,599 in reported general payments places this provider in the 85th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 122 | $70,880 |
| RestasisCyclosporine | 53 | $70,481 |
| XiidraLifitegrast | 33 | $55,769 |
| RocklatanNetarsudil Mesylat/Latanoprost | 96 | $48,113 |
| Latanoprost | 1,570 | $20,856 |
| CombiganBrimonidine Tartrate/Timolol | 49 | $19,828 |
| RhopressaNetarsudil Mesylate | 28 | $19,168 |
| ProlensaBromfenac Sodium | 54 | $18,768 |
| Cyclosporine | 26 | $16,618 |
| Acetazolamide | 206 | $11,781 |
| Travoprost | 68 | $11,465 |
| VyzultaLatanoprostene Bunod | 19 | $9,845 |
| Bromfenac Sodium | 46 | $8,531 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 26 | $7,167 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 22 | $7,038 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $2,610 | $161,189224 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $36 | $67,281124 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $37 | $65,61552 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $232 | $18,76854 claims |
| AlconSimbrinza | $4,196 | $7,03822 claims |
| NovartisIlevro | $422 | $6,59018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,405 ophthalmology providers in Florida.
Other ophthalmology in Mount Dora
- Jeffrey BaumannMount Dora$388K
- David EichenbaumSt Petersburg$34.4M
- Robert RadenDelray Beach$7.8M
- Carl DanzigPompano Beach$5.3M
- Bruce SegalDelray Beach$4.7M
- Cathleen McCabeBradenton$4.6M
- Ivan SunerTampa$3.7M
- Sunir JoshiFt Lauderdale$3.7M
- Harold BrooksTallahassee$3.5M
- Matthew CunninghamOrlando$2.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.